MediPharm Labs Corp. (MEDIF) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

MediPharm Labs Corp.

MEDIF

OTC

Unprofitable

EPS improving

Unprofitable

EPS improving

21M

Drug Manufacturers - Specialty & Generic

Next Earning date - 12 Aug 2025

21M

Drug Manufacturers - Specialty & Generic

Next Earning date - 12 Aug 2025

0.05USD

-0.00 ( -0.39%)

Market Open

Relative Strenght

Volume Buzz

-90%

Earning Acce

Yes

Dist 52w H.

40%

Quote Panel

Updated August 3, 2025

1W -0.19 % 1M 0.59 % 3M -20.53 % 1Y 14.00 %

Key Metrics

Market Cap
20.77M
Shares Outstanding
404.82M
Share in Float
387.26M
Dividende
0

Earning Date
12 Aug 2025
Price Target
0.0513
Average Volume
139616
Beta
0.927

Range
0.037-0.085
Industry
Drug Manufacturers - Specialty & Generic
Website
https://www.medipharmlabs.com
Sector
Healthcare

Quote Panel

Updated August 3, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

N/A

P/E Ratio

0.64x

P/S Ratio

0.62x

P/B Ratio

0.0

Debt/Equity

-17.4%

Net Margin

$-0.0

EPS

How MEDIF compares to sector?

P/E Ratio

Fundamentals

Relative Strength

MEDIF

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

MEDIF

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$50M

367%

2026-Revenue

$0.39

43901%

2026-EPS

$35M

-65414%

2026-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

No Data Available

Forecast

Analyst rating

Last analyst upgrade/downgrade

MediPharm Labs Corp.

MEDIF

OTC

Unprofitable

EPS improving

Unprofitable

EPS improving

21M

Drug Manufacturers - Specialty & Generic

Next Earning date - 12 Aug 2025

21M

Drug Manufacturers - Specialty & Generic

Next Earning date - 12 Aug 2025

0.05USD

-0.00 ( -0.39%)

Relative Strenght

Volume Buzz

-90%

Earning Acce

Yes

Dist 52w H.

40%

Earnings Growth

YoY

Current

Estimates

Q1.23

N/A

-0.02
vs -0.03

Q2.23

N/A

-0.01
vs -0.03

Q3.23

N/A

-0.01
vs -0.03

Q4.23

N/A

-0.01
vs -0.01

Q1.24

N/A

-0.01
vs -0.02

Q2.24

N/A

-0.00
vs -0.01

Q3.24

N/A

-0.00
vs -0.01

Q4.24

N/A

-0.00
vs -0.01

Q1.25

N/A

-0.00
vs -0.01

Q3.25

N/A

-0.01
vs -0.00

Sales Growth

YoY

Current

Estimates

Q2.23

+120%

9.6M vs 4.4M

Q3.23

+17%

8.5M vs 7.3M

Q4.23

+63%

9.1M vs 5.6M

Q1.24

+67%

9.8M vs 5.8M

Q2.24

+8%

10.3M vs 9.6M

Q3.24

+15%

9.8M vs 8.5M

Q4.24

+32%

12M vs 9.1M

Q1.25

+11%

10.8M vs 9.8M

Q2.25

+20%

12.4M vs 10.3M

Q3.25

+42%

13.9M vs 9.8M

Return on Equity

QoQ

Q2.23

-5%

-0.05
vs -0.06

Q3.23

-8%

-0.08
vs -0.05

Q4.23

-6%

-0.06
vs -0.08

Q1.24

-7%

-0.07
vs -0.06

Q2.24

-5%

-0.05
vs -0.07

Q3.24

-6%

-0.06
vs -0.05

Q4.24

-4%

-0.04
vs -0.06

Q1.25

-1%

-0.01
vs -0.04

Institutionnal Ownership

Earnings Growth

1W -0.19 % 1M 0.59 % 3M -20.53 % 1Y 14.00 %

Market Cap
20.77M
Shares Outstanding
404.82M
Share in Float
387.26M
Dividende
0

Earning Date
12 Aug 2025
Price Target
0.0513
Average Volume
139616
Beta
0.927

Range
0.037-0.085
Industry
Drug Manufacturers - Specialty & Generic
Website
https://www.medipharmlabs.com
Sector
Healthcare

Relative Strength

MEDIF

Sector

$50M

367%

2026-Revenue

$0.39

43901%

2026-EPS

$35M

-65414%

2026-EBITDA

Strong Sell

Sell

Buy

Neutral

Strong Buy

Price Target

NaN(-100.00%)

N/A

P/E Ratio

0.64x

P/S Ratio

0.62x

P/B Ratio

0.0

Debt/Equity

-17.4%

Net Margin

$-0.0

EPS

How MEDIF compares to sector?

P/E Ratio

Company Description

0.05USD

N/A

0.64x

0.62x

0.0

-17.4%

$-0.0

$50M

$0.39

$35M

Latest News

Latest News

Company Description

0.05USD

Earnings Growth

Latest News

$50M

$0.39

$35M

N/A

0.64x

0.62x

0.0

-17.4%

$-0.0